- Home
- Publications
- Publication Search
- Publication Details
Title
Management of regorafenib-related toxicities: a review
Authors
Keywords
-
Journal
Therapeutic Advances in Gastroenterology
Volume 8, Issue 5, Pages 285-297
Publisher
SAGE Publications
Online
2015-05-08
DOI
10.1177/1756283x15580743
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.
- (2017) T. Shimizu et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
- (2014) J. Sastre et al. Clinical & Translational Oncology
- Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis
- (2014) Omar Abdel-Rahman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Laying to Rest Psychostimulants for Cancer-Related Fatigue?
- (2014) Kathryn J. Ruddy et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
- (2014) A. Grothey et al. ONCOLOGIST
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
- (2013) B. Schultheis et al. ANNALS OF ONCOLOGY
- A prospective evaluation of an interdisciplinary nutrition–rehabilitation program for patients with advanced cancer
- (2013) B. Gagnon et al. Current Oncology
- Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
- (2013) Viswanath Reddy Belum et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
- (2013) Josep Tabernero et al. EUROPEAN JOURNAL OF CANCER
- Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
- (2013) Zexing Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The EORTC computer-adaptive tests measuring physical functioning and fatigue exhibited high levels of measurement precision and efficiency
- (2013) Morten Aa. Petersen et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
- (2013) L. Abou-Elkacem et al. MOLECULAR CANCER THERAPEUTICS
- Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation
- (2013) Clemens C. Cyran et al. PLoS One
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
- (2012) D Strumberg et al. BRITISH JOURNAL OF CANCER
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy
- (2012) Thomas C. Wehler et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Evaluation of regorafenib in colorectal cancer and GIST
- (2012) Tom Waddell et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Qualitative research into the symptom experiences of adult cancer patients after treatments: a systematic review and meta-synthesis
- (2012) A. E. Bennion et al. SUPPORTIVE CARE IN CANCER
- Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites
- (2011) Dieter Zopf et al. CANCER RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
- (2010) Michael S. Ewer et al. Nature Reviews Cardiology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started